Bolt Biotherapeutics (BOLT) Competitors

$4.83 +0.05 (+1.05%)

Closing price 05/13/2026 04:00 PM Eastern

Extended Trading

$4.84 +0.01 (+0.12%)

As of 04:05 AM Eastern

BOLT vs. CRIS, AMGN, GILD, VRTX, and REGN

Should you buy Bolt Biotherapeutics stock or one of its competitors? MarketBeat compares Bolt Biotherapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Bolt Biotherapeutics include Curis (CRIS), Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), and Regeneron Pharmaceuticals (REGN). These companies are all part of the "biotechnology" industry.

How does Bolt Biotherapeutics compare to Curis?

Bolt Biotherapeutics (NASDAQ:BOLT) and Curis (NASDAQ:CRIS) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, earnings, profitability, media sentiment, institutional ownership, risk and dividends.

Bolt Biotherapeutics has a beta of 1.1, suggesting that its share price is 10% more volatile than the broader market. Comparatively, Curis has a beta of 3.08, suggesting that its share price is 208% more volatile than the broader market.

86.7% of Bolt Biotherapeutics shares are held by institutional investors. Comparatively, 30.0% of Curis shares are held by institutional investors. 9.4% of Bolt Biotherapeutics shares are held by insiders. Comparatively, 5.4% of Curis shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Curis has higher revenue and earnings than Bolt Biotherapeutics. Curis is trading at a lower price-to-earnings ratio than Bolt Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bolt Biotherapeutics	$7.70M	1.20	-$33.38M	-$17.82	N/A
Curis	$9.44M	2.12	-$7.58M	-$1.19	N/A

Bolt Biotherapeutics currently has a consensus target price of $41.00, indicating a potential upside of 748.86%. Curis has a consensus target price of $17.00, indicating a potential upside of 3,300.00%. Given Curis' higher probable upside, analysts plainly believe Curis is more favorable than Bolt Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bolt Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Curis	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Curis has a net margin of -80.29% compared to Bolt Biotherapeutics' net margin of -455.15%. Curis' return on equity of 0.00% beat Bolt Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bolt Biotherapeutics	-455.15%	-91.06%	-44.98%
Curis	-80.29%	N/A	-188.78%

In the previous week, Curis had 4 more articles in the media than Bolt Biotherapeutics. MarketBeat recorded 9 mentions for Curis and 5 mentions for Bolt Biotherapeutics. Bolt Biotherapeutics' average media sentiment score of -0.06 beat Curis' score of -0.09 indicating that Bolt Biotherapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bolt Biotherapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Curis	0 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Curis beats Bolt Biotherapeutics on 9 of the 16 factors compared between the two stocks.

How does Bolt Biotherapeutics compare to Amgen?

Bolt Biotherapeutics (NASDAQ:BOLT) and Amgen (NASDAQ:AMGN) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, earnings, profitability, media sentiment, institutional ownership, risk and dividends.

Bolt Biotherapeutics has a beta of 1.1, suggesting that its share price is 10% more volatile than the broader market. Comparatively, Amgen has a beta of 0.44, suggesting that its share price is 56% less volatile than the broader market.

86.7% of Bolt Biotherapeutics shares are held by institutional investors. Comparatively, 76.5% of Amgen shares are held by institutional investors. 9.4% of Bolt Biotherapeutics shares are held by insiders. Comparatively, 0.9% of Amgen shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Amgen has higher revenue and earnings than Bolt Biotherapeutics. Bolt Biotherapeutics is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bolt Biotherapeutics	$7.70M	1.20	-$33.38M	-$17.82	N/A
Amgen	$37.22B	4.88	$7.71B	$14.37	23.41

Bolt Biotherapeutics currently has a consensus target price of $41.00, indicating a potential upside of 748.86%. Amgen has a consensus target price of $356.35, indicating a potential upside of 5.91%. Given Bolt Biotherapeutics' higher probable upside, equities analysts plainly believe Bolt Biotherapeutics is more favorable than Amgen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bolt Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Amgen	2 Sell rating(s)	14 Hold rating(s)	13 Buy rating(s)	2 Strong Buy rating(s)	2.48

Amgen has a net margin of 20.96% compared to Bolt Biotherapeutics' net margin of -455.15%. Amgen's return on equity of 137.41% beat Bolt Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bolt Biotherapeutics	-455.15%	-91.06%	-44.98%
Amgen	20.96%	137.41%	13.28%

In the previous week, Amgen had 27 more articles in the media than Bolt Biotherapeutics. MarketBeat recorded 32 mentions for Amgen and 5 mentions for Bolt Biotherapeutics. Amgen's average media sentiment score of 1.00 beat Bolt Biotherapeutics' score of -0.06 indicating that Amgen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bolt Biotherapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Amgen	18 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Amgen beats Bolt Biotherapeutics on 13 of the 17 factors compared between the two stocks.

How does Bolt Biotherapeutics compare to Gilead Sciences?

Gilead Sciences (NASDAQ:GILD) and Bolt Biotherapeutics (NASDAQ:BOLT) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, dividends, risk, earnings, profitability, media sentiment and valuation.

Gilead Sciences has higher revenue and earnings than Bolt Biotherapeutics. Bolt Biotherapeutics is trading at a lower price-to-earnings ratio than Gilead Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gilead Sciences	$29.44B	5.61	$8.51B	$7.34	18.13
Bolt Biotherapeutics	$7.70M	1.20	-$33.38M	-$17.82	N/A

Gilead Sciences has a beta of 0.31, indicating that its share price is 69% less volatile than the broader market. Comparatively, Bolt Biotherapeutics has a beta of 1.1, indicating that its share price is 10% more volatile than the broader market.

83.7% of Gilead Sciences shares are owned by institutional investors. Comparatively, 86.7% of Bolt Biotherapeutics shares are owned by institutional investors. 0.3% of Gilead Sciences shares are owned by company insiders. Comparatively, 9.4% of Bolt Biotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Gilead Sciences had 60 more articles in the media than Bolt Biotherapeutics. MarketBeat recorded 65 mentions for Gilead Sciences and 5 mentions for Bolt Biotherapeutics. Gilead Sciences' average media sentiment score of 0.62 beat Bolt Biotherapeutics' score of -0.06 indicating that Gilead Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Gilead Sciences	24 Very Positive mention(s)	9 Positive mention(s)	10 Neutral mention(s)	10 Negative mention(s)	3 Very Negative mention(s)	Positive
Bolt Biotherapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Gilead Sciences presently has a consensus target price of $157.04, indicating a potential upside of 18.03%. Bolt Biotherapeutics has a consensus target price of $41.00, indicating a potential upside of 748.86%. Given Bolt Biotherapeutics' higher possible upside, analysts clearly believe Bolt Biotherapeutics is more favorable than Gilead Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gilead Sciences	0 Sell rating(s)	4 Hold rating(s)	24 Buy rating(s)	0 Strong Buy rating(s)	2.86
Bolt Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Gilead Sciences has a net margin of 30.99% compared to Bolt Biotherapeutics' net margin of -455.15%. Gilead Sciences' return on equity of 48.19% beat Bolt Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gilead Sciences	30.99%	48.19%	18.28%
Bolt Biotherapeutics	-455.15%	-91.06%	-44.98%

Summary

Gilead Sciences beats Bolt Biotherapeutics on 12 of the 16 factors compared between the two stocks.

How does Bolt Biotherapeutics compare to Vertex Pharmaceuticals?

Vertex Pharmaceuticals (NASDAQ:VRTX) and Bolt Biotherapeutics (NASDAQ:BOLT) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, dividends, risk, earnings, profitability, media sentiment and valuation.

Vertex Pharmaceuticals has higher revenue and earnings than Bolt Biotherapeutics. Bolt Biotherapeutics is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vertex Pharmaceuticals	$12.00B	9.58	$3.95B	$16.86	26.87
Bolt Biotherapeutics	$7.70M	1.20	-$33.38M	-$17.82	N/A

Vertex Pharmaceuticals has a beta of 0.3, indicating that its share price is 70% less volatile than the broader market. Comparatively, Bolt Biotherapeutics has a beta of 1.1, indicating that its share price is 10% more volatile than the broader market.

91.0% of Vertex Pharmaceuticals shares are owned by institutional investors. Comparatively, 86.7% of Bolt Biotherapeutics shares are owned by institutional investors. 0.2% of Vertex Pharmaceuticals shares are owned by company insiders. Comparatively, 9.4% of Bolt Biotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Vertex Pharmaceuticals had 25 more articles in the media than Bolt Biotherapeutics. MarketBeat recorded 30 mentions for Vertex Pharmaceuticals and 5 mentions for Bolt Biotherapeutics. Vertex Pharmaceuticals' average media sentiment score of 0.98 beat Bolt Biotherapeutics' score of -0.06 indicating that Vertex Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vertex Pharmaceuticals	16 Very Positive mention(s)	1 Positive mention(s)	10 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Bolt Biotherapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Vertex Pharmaceuticals presently has a consensus target price of $555.17, indicating a potential upside of 22.54%. Bolt Biotherapeutics has a consensus target price of $41.00, indicating a potential upside of 748.86%. Given Bolt Biotherapeutics' higher possible upside, analysts clearly believe Bolt Biotherapeutics is more favorable than Vertex Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vertex Pharmaceuticals	0 Sell rating(s)	5 Hold rating(s)	20 Buy rating(s)	1 Strong Buy rating(s)	2.85
Bolt Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Vertex Pharmaceuticals has a net margin of 35.51% compared to Bolt Biotherapeutics' net margin of -455.15%. Vertex Pharmaceuticals' return on equity of 23.86% beat Bolt Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vertex Pharmaceuticals	35.51%	23.86%	17.13%
Bolt Biotherapeutics	-455.15%	-91.06%	-44.98%

Summary

Vertex Pharmaceuticals beats Bolt Biotherapeutics on 14 of the 17 factors compared between the two stocks.

How does Bolt Biotherapeutics compare to Regeneron Pharmaceuticals?

Regeneron Pharmaceuticals (NASDAQ:REGN) and Bolt Biotherapeutics (NASDAQ:BOLT) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, risk, profitability, dividends, earnings and media sentiment.

Regeneron Pharmaceuticals has a beta of 0.3, indicating that its share price is 70% less volatile than the broader market. Comparatively, Bolt Biotherapeutics has a beta of 1.1, indicating that its share price is 10% more volatile than the broader market.

Regeneron Pharmaceuticals has higher revenue and earnings than Bolt Biotherapeutics. Bolt Biotherapeutics is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Regeneron Pharmaceuticals	$14.34B	5.31	$4.50B	$41.04	17.54
Bolt Biotherapeutics	$7.70M	1.20	-$33.38M	-$17.82	N/A

In the previous week, Regeneron Pharmaceuticals had 15 more articles in the media than Bolt Biotherapeutics. MarketBeat recorded 20 mentions for Regeneron Pharmaceuticals and 5 mentions for Bolt Biotherapeutics. Regeneron Pharmaceuticals' average media sentiment score of 1.22 beat Bolt Biotherapeutics' score of -0.06 indicating that Regeneron Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Regeneron Pharmaceuticals	13 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive
Bolt Biotherapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Regeneron Pharmaceuticals has a net margin of 29.65% compared to Bolt Biotherapeutics' net margin of -455.15%. Regeneron Pharmaceuticals' return on equity of 13.16% beat Bolt Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Regeneron Pharmaceuticals	29.65%	13.16%	10.17%
Bolt Biotherapeutics	-455.15%	-91.06%	-44.98%

83.3% of Regeneron Pharmaceuticals shares are owned by institutional investors. Comparatively, 86.7% of Bolt Biotherapeutics shares are owned by institutional investors. 7.0% of Regeneron Pharmaceuticals shares are owned by company insiders. Comparatively, 9.4% of Bolt Biotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Regeneron Pharmaceuticals presently has a consensus target price of $826.59, indicating a potential upside of 14.82%. Bolt Biotherapeutics has a consensus target price of $41.00, indicating a potential upside of 748.86%. Given Bolt Biotherapeutics' higher probable upside, analysts plainly believe Bolt Biotherapeutics is more favorable than Regeneron Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Regeneron Pharmaceuticals	0 Sell rating(s)	8 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	2.77
Bolt Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Summary

Regeneron Pharmaceuticals beats Bolt Biotherapeutics on 13 of the 17 factors compared between the two stocks.

Get Bolt Biotherapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BOLT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BOLT vs. The Competition

Export

Metric	Bolt Biotherapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$9.19M	$3.42B	$6.30B	$12.28B
Dividend Yield	N/A	2.30%	2.79%	5.30%
P/E Ratio	-0.30	18.67	21.03	25.58
Price / Sales	1.20	305.47	554.66	78.88
Price / Cash	N/A	122.51	42.94	55.34
Price / Book	0.35	6.75	9.78	6.66
Net Income	-$33.38M	$24.11M	$3.55B	$333.63M
7 Day Performance	5.23%	-0.53%	-0.52%	-0.12%
1 Month Performance	1.90%	0.34%	1.21%	3.93%
1 Year Performance	-31.00%	78.62%	41.26%	36.07%

Bolt Biotherapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BOLT Bolt Biotherapeutics	3.0689 of 5 stars	$4.83 +1.0%	$41.00 +748.9%	-30.0%	$9.19M	$7.70M	N/A	90	Positive News Earnings Report Short Interest Decrease
CRIS Curis	2.6284 of 5 stars	$0.57 -1.8%	$17.00 +2,881.4%	-76.4%	$23.22M	$9.44M	N/A	60	News Coverage Earnings Report Gap Down
AMGN Amgen	3.8594 of 5 stars	$329.59 +1.8%	$357.12 +8.4%	+24.4%	$174.78B	$36.75B	22.94	31,500	Analyst Forecast
GILD Gilead Sciences	4.6141 of 5 stars	$133.48 +0.6%	$157.35 +17.9%	+31.2%	$164.70B	$29.44B	19.72	17,000	Earnings Report Analyst Forecast
VRTX Vertex Pharmaceuticals	4.2981 of 5 stars	$424.36 -1.3%	$554.83 +30.7%	+4.9%	$109.34B	$12.00B	25.17	6,400	Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BOLT) was last updated on 5/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Bolt Biotherapeutics (BOLT) Competitors

BOLT vs. CRIS, AMGN, GILD, VRTX, and REGN

How does Bolt Biotherapeutics compare to Curis?

Summary

How does Bolt Biotherapeutics compare to Amgen?

Summary

How does Bolt Biotherapeutics compare to Gilead Sciences?

Summary

How does Bolt Biotherapeutics compare to Vertex Pharmaceuticals?

Summary

How does Bolt Biotherapeutics compare to Regeneron Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BOLT vs. The Competition

Bolt Biotherapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Bolt Biotherapeutics (BOLT) Competitors

BOLT vs. CRIS, AMGN, GILD, VRTX, and REGN

How does Bolt Biotherapeutics compare to Curis?

Which has more risk and volatility, BOLT or CRIS?

Do institutionals & insiders believe in BOLT or CRIS?

Which has higher valuation and earnings, BOLT or CRIS?

Do analysts prefer BOLT or CRIS?

Is BOLT or CRIS more profitable?

Does the media refer more to BOLT or CRIS?

Summary

How does Bolt Biotherapeutics compare to Amgen?

Which has more risk and volatility, BOLT or AMGN?

Do institutionals & insiders believe in BOLT or AMGN?

Which has higher valuation and earnings, BOLT or AMGN?

Do analysts prefer BOLT or AMGN?

Is BOLT or AMGN more profitable?

Does the media refer more to BOLT or AMGN?

Summary

How does Bolt Biotherapeutics compare to Gilead Sciences?

Which has better earnings & valuation, GILD or BOLT?

Which has more risk and volatility, GILD or BOLT?

Do insiders and institutionals believe in GILD or BOLT?

Does the media prefer GILD or BOLT?

Do analysts recommend GILD or BOLT?

Is GILD or BOLT more profitable?

Summary

How does Bolt Biotherapeutics compare to Vertex Pharmaceuticals?

Which has better earnings & valuation, VRTX or BOLT?

Which has more risk and volatility, VRTX or BOLT?

Do insiders and institutionals believe in VRTX or BOLT?

Does the media prefer VRTX or BOLT?

Do analysts recommend VRTX or BOLT?

Is VRTX or BOLT more profitable?

Summary

How does Bolt Biotherapeutics compare to Regeneron Pharmaceuticals?

Which has more volatility & risk, REGN or BOLT?

Which has preferable earnings and valuation, REGN or BOLT?

Does the media favor REGN or BOLT?

Is REGN or BOLT more profitable?

Do institutionals and insiders have more ownership in REGN or BOLT?

Do analysts recommend REGN or BOLT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BOLT vs. The Competition

Bolt Biotherapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools